BetterLife Pharma Inc.
BetterLife Pharma Inc.
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
BetterLife Pharma Inc. (BETR)
SEDAR Information
Company Info
Capitalization
News Releases
Bulletins
2020-0836 – Fundamental Change - BetterLife Pharma Inc. (BETR)
Le 31 aout/August 2020
Following a fundamental change review the common shares of BetterLife Pharma Inc. have requalified for listing.
Listing and disclosure documents will be available at www.thecse.com on the trading date.